Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.

Decloedt, E H; Reuter, H; Allwood, B; Parker, A; Koegelenberg, C F N; Blockman, M; Taljaard, J

Decloedt, E H; Reuter, H; Allwood, B; Parker, A; Koegelenberg, C F N; Blockman, M; Taljaard, J.

Decloedt EH; Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa. ericdecloedt@sun.ac.za.

S Afr Med J ; 110(5): 12903, 2020 04 02.

Article in English | MEDLINE | ID: covidwho-994136

Subject(s)

Chloroquine; Coronavirus Infections; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Azithromycin; Betacoronavirus; COVID-19; Coronavirus Infections/drug therapy; Humans; SARS-CoV-2; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Chloroquine / Coronavirus Infections / Pandemics / Hydroxychloroquine Type of study: Prognostic study Limits: Humans Language: English Journal: S Afr Med J Year: 2020 Document Type: Article Affiliation country: Samj.2020.v110i5.14761

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google